Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Pasteur Says It Cannot Meet MHWL Request to Lower IPV Price
September 11, 2012
- Eisai Receives Australian Approval for Halaven
September 10, 2012
- DSP Revising Midterm Business Plan – Will It Be Able to Hammer Out Effective Measures against Stagnant Domestic Business?
September 10, 2012
- Fuji-Keizai Predicts Antidepressant Market to Exceed 170 Billion Yen in 2020
September 7, 2012
- Kissei Aims for 40% Market Share for Epoetin Alfa at Early Stage
September 7, 2012
- Kyorin to Appoint Yoshida of MSD as Kyorin Pharmaceutical Facilities President
September 7, 2012
- Sunovion Completes Acquisition of Elevation: DSP
September 7, 2012
- Revestive Receives European Market Authorization for Short Bowel Syndrome: Takeda
September 6, 2012
- Nippon Shinyaku Plans Generic Launch to Complement Its New Drug Lineup in Priority Field
September 6, 2012
- AZ Aims to Become Market Leader with Symbicort on Additional Indication for COPD
September 6, 2012
- DSP Submits Imported Drug Registration Application in China for Anticancer Agent Calsed
September 6, 2012
- Meiji Seika Pharma Aims to Bolster Presence with COPD Drug Oxis
September 5, 2012
- Flu Vaccine Deal with BIKEN Hoped to Yield Synergies in Elderly Products: MSD Pres. Alvarez
September 5, 2012
- Anticancer Agent Enzalutamide Approved in the US: Astellas
September 5, 2012
- Halaven Approved in South Korea, To Be Launched in Jan. 2013: Eisai
September 5, 2012
- RaQualia to Focus on Fields Where It Can Exhibit Uniqueness, Compile Biz Strategy in November
September 4, 2012
- “Advancements in Domestic Business is Growth Driver” for Achieving Midterm Business Plan : MTPC President Tsuchiya
September 4, 2012
- Ono Ties Up with BioFocus of the UK for Drug Discovery for CNS Disorders
September 4, 2012
- Meiji Seika Pharma Launches COPD Treatment Oxis, Detailed by More Than 600 MRs
September 4, 2012
- Otsuka Applies for Abilify as Adjunctive Therapy for Depression; First Indication for Antipsychotic Drug in Japan
September 4, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…